BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Visient Therapeutics, Inc. Treats First Patient In Phase 1 Trial Of Litx(TM) For Advanced Age-Related Macular Degeneration


10/19/2005 5:12:50 PM

SEATTLE, Feb. 24 /PRNewswire/ -- Visient Therapeutics announced today that it has enrolled the first patient in a newly commenced Phase 1 clinical trial evaluating Litx in patients with advanced age-related macular degeneration. Ophthalmologist Gary Edd Fish, M.D., treated the patient at Texas Retina Associates in Dallas.

The Food & Drug Administration (FDA) accepted an Investigational New Drug (IND) application in 2004. This permitted Visient Therapeutics to begin an open-label, dose escalation safety trial using the light-activated drug LS11 (talaporfin sodium) to treat patients with advanced age-related macular degeneration (AMD). In this study, LS11 will be administered to patients intravenously, and then activated selectively in diseased portions of the eye by light.

"Beginning our ophthalmic clinical trials for AMD is a significant accomplishment for Visient," said Albert Luderer, Ph.D., President of Visient Therapeutics and President and CEO of parent company, Light Sciences. "The quick acceptance of our IND by the FDA really underscores the safety profile that we have seen with this compound. We believe that our unique approach may solve many of the major problems associated with currently available therapies, such as poor response rates, inadequate durability of visual stabilization and uncomfortable drug delivery mechanisms."

AMD is the leading cause of irreversible blindness for those aged 55 and over. Nearly 200,000 people are diagnosed with AMD in the United States every year.

About Visient Therapeutics

Visient Therapeutics is wholly owned subsidiary of Light Sciences Corporation. Light Sciences Corporation, founded in 1995, is a privately owned company developing Light Infusion Technology (Litx), a proprietary combination product comprising a photo-reactive agent (LS11) activated by non-coherent light infusion devices. Litx represents an important step forward in the clinical application of light activated drugs in cancer, cardiovascular, eye and many other diseases. For additional information about Light Sciences, please visit http://www.lightsciences.com/ .

NOTE: Light Sciences(R), Litx(TM) and Light Infusion Technology(TM) are registered or proprietary marks of Light Sciences Corporation.

Contact: Al Luderer President and CEO Visient Therapeutics 425-369-2800 info@lightsci.com Kristie Kuhl Makovsky & Co. 212-508-9642 kkuhl@makovsky.com

Visient Therapeutics

CONTACT: Al Luderer, President and CEO of Visient Therapeutics,+1-425-369-2800, or info@lightsci.com; or Kristie Kuhl of Makovsky & Co.,+1-212-508-9642, or kkuhl@makovsky.com, for Visient Therapeutics



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES